Befloxatone. Antidepressant MAO-A inhibitor

Drugs of the Future

Volumn 24, Issue 10, 1999, Pages 1057-1067

  Rabasseda, X ^a   Sorbera, L A ^a   Castaner J ^a  

^a NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 TRIFLUOROMETHYL)ETHOXYPHENOXATHIIN 10,10 DIOXIDE; 3 (6 CYCLOPROPYLMETHOXY 2 NAPHTHYL) 5 METHOXYMETHYL 2 OXAZOLIDONE; 3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BEFLOXATONE; BENZYLAMINE; DOPAMINE; GLYCINAMIDE DERIVATIVE; KP 9; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PHENETHYLAMINE; SEROTONIN; SEROTONIN RECEPTOR; SL 650477; TETRINDOL; TOLOXATONE; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE; UNCLASSIFIED DRUG; UR 1827;

BLOOD PRESSURE; BRAIN; CLINICAL TRIAL; DEPRESSION; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW;

EID: 0032696321     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.10.549515     Document Type: Review

References (46)

1. Jarreau, F.-X., Rovei, V., Koening, J.-J., Schoofs, A. (Synthélabo). 3-Aryl oxazolidinones, process for their preparation and their therapeutical use. EP 424244.
2. Jarreau, F.-X., Koening, J.-J., Rovei, V. (Synthélabo). 3-Aryl-oxazolidinone derivs., process for their preparation and their use in therapeutics. EP 511031.
3. Mihashi, S., Kondo, H. (Takasago Corp.). Fluorine-containing liquid crystal compound. JP 89003154.
4. Tixidre, A., Zard, L., Rossey, G., Bourbon, A. (Synthélabo). Process for the enzymatic preparation of an intermediate in the synthesis of befloxatone. EP 736606.
5. Jarreau, F.-X., Rovei, V., Koening, J.-J., Schoofs, A. (Delalande SA). 3-Aryl oxazolidinones, process for their preparation and their therapeutical use. EP 424243.
6. Greenawalt, J.W., Schnaitman, C. An appraisal of the use of monoamine oxidase as an enzyme marker for the outer membrane of rat liver mitochondria. J Cell Biol 1970, 46: 173-9.
7. Westlund, K.N., Krakower, T.J., Kwan, S.W., Abell, C.W. Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res 1993, 612:221-30.
8. Youdim, M.B.H., Finberg, J.P.M. Monoamine oxidase inhibitor antidepressants. In: Psychopharmacology 2. Part I. Preclinical Psychopharmacology, D.G. Grahame-Smith (Ed.), Elsevier Science Publishers B.V., Amsterdam, 1985, 35-70.
9. Youdim, M.B.H., Finberg, J.P.M., Tipton, K.F. Monoamine oxidase. In: Catecholamines. I. Handbook of Experimental Pharmacology, Vol. 90, U. Trendelenburg, N. Weiner (Eds.), Springer-Verlag, Berlin, 1988, 119-92.
10. Strolin-Benedetti, M., Dostert, P Stereochemical aspects of MAO interactions: Reversible and selective inhibitors of monoamine oxidase. Trends Pharmacol Sci 1985, 6: 246-51.
11. Blackwell, B. Adverse effects of antidepressant drugs. Part 1: monoamine oxidase inhibitors and tricyclics. Drugs 1981, 21: 201-19.
12. Bieck, P.R., Antonin, K.-H. Tyramine potentiation during treatment with MAOIs. In: Clinical Advances in Monoamine Oxidase Inhibitor Therapies, S.H. Kennedy (Ed.), American Psychiatry Press, Washington DC, 1994, 83-110.
13. Wouters, J., Moureau, F., Evrard, G., Koening, J.-J., Jegham, S., George, P., Durant, F. A reversible monoamine oxidase A inhibitor, befloxatone: Structural approach of its mechanism of action. Bioorg Med Chem 1999, 7: 1683-93.
14. Curet, O., Damoiseau, G., Aubin, N., Sontag, N., Rovei, V., Jarreau, F.-X. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J Pharmacol Exp Ther 1996 277: 253-64.
15. Curet, O., Damoiseau-Ovens, G., Sauvage, C., Sontag, N., Avenet, P., Depoortere, H., Caille, D., Bergis, O., Scatton, B. Preclinical profile of befloxatone, a new reversible MAO-A inhibitor. J Affect Disord 1998, 51: 287-303.
16. 3H]-Ro-19-6327 in vitro: Localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 1992, 12: 1977-99.
17. Curet, O., Damoiseau, J.-P., Labaune, V., Rovel, V., Jarreau, F.-X. Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monoamines in freely moving rats. J Neural Transm Suppl 1994, 41: 349-55.
18. Haddjeri, N., De Montigny, C., Curet, O., Blier, P. Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission. Eur J Pharmacol 1998, 343: 179-92.
19. Ego, D., Parisy, D., Pattano, N. Pharmacokinetics of befloxatone, a new reversible inhibitor of MAO-A in rat. Clin Neuropharmacol 1992, 15(Suppl. 1, Part 2): 422B.
20. Caille, D., Bergis, O.-E., Fankhauser, C., Gardes, A., Adam, R., Charieras, T., Grosset, A., Rovei, V., Jarreau, F.-X. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J Pharmacol Exp Ther 1996, 277: 265-77.
21. Patat, A., Gandon, J.M., Durrieu, G., Le Coz, F., Curet, O., Cimarosti, I., Allain, H. Effects of single and multiple doses of a new reversible MAO-A inhibitor, befloxatone, on psychomotor performance and memory in healthy subjects. Hum Psychopharmacol 1995, 10: 111-25.
22. Patat, A., Warot, D., Berlin, I., Durrieu, G., Zieleniuk, I., Puech, A. Effects of befloxatone on psychomotor performance and memory. Br J Clin Pharmacol 1995, 39: 565P.
23. Rosenzweig, P., Patat, A., Curet, O., Durrieu, G., Dubruc, C., Zieleniuk, I., Legangneux, E. Clinical pharmacology of befloxatone: A brief review. J Affect Disord 1998, 51: 305-12.
24. Patat, A., Dubruc, C., Deschamp, C., Durrieu, C., Trocherie, S., Cimarosti, I., Allain, H., Rosenzweig, P., Gandon, J.-M. EEG, MAO-A inhibition, pharmacokinetics and safety of befloxatone in the elderly. Hum Psychopharmacol 1997, 12: 557-71.
25. Ramaekers, J.G., Muntjewerff, N.D., Patat, A., Durrieu, G., O'Hanlon, J.F. The interaction between befloxatone and ethanol on psychomotor performance. J Psychopharmacol 1995, 9(3, Suppl.): Abst 151.
26. Durrieu, G., Patat, A., Berlin, I., Armand, P., Molinier, P., Caille, P., Rosenzweig, P. Oral tyramine pressor effect after chronic treatment with befloxatone in healthy volunteers. Br J Clin Pharmacol 1995, 39: 574P.
27. Pinquier, J.L., Caplain, H., Durrieu, G., Zieleniuk, I., Rosenzweig, P. Safety and pharmacodynamic study of befloxatone (B) after fluoxetine (F) withdrawal. Clin Pharmacol Ther 1998, 63: Abst PII-60.
28. Pinquier, J.L, Patat, A., Durrieu, G., Zieleniuk, I., Allain, H., Gandon, J.M., Rosenzweig, P. Safety and pharmacodynamic study of befloxatone after imipramine withdrawal in healthy volunteers. J Clin Pharmacol 1997, 37: Abst 46.
29. Patat, A., Le Coz, F., Gandon, J.M., Beck, A., Durrieu, G., Curet, O., Allain, H. Use of free DHPG plasma levels to assess equipotency of 2 dosage regimens of befloxatone, a reversible MAO-A inhibitor. Clin Pharmacol Ther 1995, 57: Abst PI-46.
30. Allain, H., Patat, A., Gardon, J.M., Le Coz, F., Raoul, P., Durrieu, G, Effects on psychomotor and cognitive functions of multiple doses of befloxatone. Eur J Clin Invest 1995, 25(Suppl. 2): Abst 365.
31. Ansseau, M., Caille, P., Derks, C., Cieren-Puiseux, I., Wauthy, J., Ego, D., Curet, O., Thiola, A., Rovei, V., Jarreau, F.X. Phase I study of single ascending doses of befloxatone, a new reversible MAO-A inhibitor antidepressant. Clin Neuropharmacol 1992, 15(Suppl. 1, Part B): 328B.
32. Ansseau, M., Caille, P., Derks, C., Cieren-Puiseux, I., Wauthy, J., Ego, D., Rovei, D., Jarreau, F.X. Phase I study of repeated doses of befloxatone, a new reversible MAO-A inhibitor antidepressant. Clin Neuropharmacol 1992, 15(Suppl. 1, Part B): 328B.
33. Warot, D., Berlin, I., Patat, A., Durrieu, G., Zieleniuk, I., Puech, A.J. Effects of befloxatone, a reversible selective monoamine oxidase-A inhibitor, on psychomotor function and memory in healthy subjects. J Clin Pharmacol 1996, 36: 942-50.
34. Patat, A., Allain, H., Le Coz, R, Durrieu, G., Cimarosti, I., Rosenzweig, P., Gandon, J.M. Effects of befloxatone on cognitive functions in the elderly. Biol Psychiatry 1997, 42(1, Suppl.): Abst 90-21.
35. Patat, A., Trocherie, S., Durrieu, G., Cimarosti, I., Allain, H., Gandon, J.M., Rosenzweig, P. Effects of befloxatone on EEG and cognitive functions in elderly subjects. Br J Clin Pharmacol 1997, 43: 552P.
36. Patat, A., Berlin, I., Durrieu, G., Armand, P., Fitoussi, S., Molinier, P., Caille, P. Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects. J Clin Pharmacol 1995, 35: 633-43.
37. Luthringer, R., Dago, K.T., Patat, A., Caille, P., Curet, O., Durieu, G., Rinaudo, G., Toussaint, M., Granier, L.A., Macher, J.P. Pharmacoelectroencephalographic profile of befloxatone, a new reversible MAO-A inhibitor, in healthy subjects. Neuropsychobiology 1996, 34: 98-105.
38. Patat, A., Gandon, J.M., Le Coz, F., Durrieu, G., Cimarosti, I., Allain, H., Caroff, J., Rosenzweig, P. Safety and MAO-A inhibition of befloxatone in elderly subjects. Therapie 1995, Suppl.: Abst 104.
39. Patat, A., Gandon, J.M., Le Coz, F., Raoul, P., Beck, A., Durrieu, G., Curet, O., Allain, H. Lack of impairment of psychomotor performance and cognitive functions after multiple doses of befloxatone. Neuropsychopharmacology 1994, 10(3S, Part 2): Abst P-117-34.
40. Patat, A., Le Coz, F., Dubruc, C. et al. Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers. J Clin Pharmacol 1996, 36: 216-29.
41. Befloxatone development status. Sanofi-Synthélabo Company Communication 1999, August 16.
42. Bruhwyler, J., Liegeois, J.F., Gerardy, J., Damas, J., Chleide, E., Lejeune, C., Decamp, E., de Tullio, P., Delarge, J., Dresse, A., Geczy, J. Comparative study of pirlindole, a selective RIMA, and its two enantiomers using biochemical and behavioural techniques. Behav Pharmacol 1998, 9: 731-7.
43. Medvedev, A.E., Kirkel, A.A., Kamyshanskaya, N.S., Moskvitina, T.A., Axenova, L.N., Gorkin, V.Z., Andreeva, N.I., Golovina, S.M., Mashkovsky, M.D. Monoamine oxidase inhibition by novel antidepressant tetrindole. Biochem Pharmacol 1994, 47: 303-8.
44. Kato, M., Katayama, T., Iwata, H., Yamamura, M., Matsuoka, Y., Narita, H. In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin. J Pharmacol Exp Ther 1998, 284: 983-90.
45. Van der Meersch-Mougeot, V., da Rocha, M. Jr., Monier, C., Diquet, B., Puech, A.J., Thiebot, M.H. Benzodiazepines reverse the anti-immobility effect of antidepressants in the forced swimming test in mice. Neuropharmacology 1993, 32: 439-46.
46. Glushkov, R.G., Mashkovsky, M.D., Andrejeva, N.I. Tetrindole. Drugs Fut 1997, 22: 1333-5.